Sacubitril/Valsartan Improves Progression of Early Diabetic Nephropathy in Rats Through Inhibition of NLRP3 Inflammasome Pathway
Yan Pan,Lei Liu,Huijuan Yang,Weidong Chen,Zheng Chen,Jing Xu
DOI: https://doi.org/10.2147/DMSO.S366518
2022-08-14
Abstract:Yan Pan, Lei Liu, Huijuan Yang, Weidong Chen, Zheng Chen, Jing Xu Department of Nephrology, First Affiliated Hospital of Bengbu Medical College, Bengbu City, People's Republic of China Correspondence: Yan Pan, Department of Nephrology, First Affiliated Hospital of Bengbu Medical College, No. 287, Changhuai Road, Longzihu District, Bengbu City, Anhui Province, 233000, People's Republic of China, Tel +86 13865030612, Email Purpose: Diabetic nephropathy (DN), a global disease, is the leading cause of end-stage renal disease. There is a lack of specific treatment for this disease, and early intervention in disease progression is essential. In this paper, we used a rat model of early diabetic nephropathy to explore the therapeutic mechanism of sacubitril/valsartan in rats with early diabetic nephropathy. Materials and Methods: Rats were grouped into 1 normal group; 2. Model group (DN group): STZ (45 mg/kg/d) induced early diabetic nephropathy rats; 3. Sac group: DN rats + Sac group (orally, 60 mg/kg/d) for 6 weeks. After 6 weeks, the levels of serum albumin (ALB), glucose (GLU), creatinine (Cr), urea nitrogen (BUN) and 24-h urinary protein excretion were measured. In renal tissue homogenates, NLRP3 inflammasome, proinflammatory factors IL1-β and TNF-α, oxidative stress MDA and pro-fibrotic cytokine TGF-β 1 were performed. Histological analysis of kidneys by hematoxylin and eosin (HE), PAS and Masson trichrome staining. Results: 1. Sacubitril/valsartan (Sac) significantly improved renal hypertrophy, proteinuria and serum albumin levels in rats with early diabetic nephropathy (P < 0.001), and decreased GLU, Scr (P< 0.001), and BUN levels (P < 0.01).2. Light microscopy of renal tissues showed glomerular hypertrophy and interstitial inflammatory cell infiltration, and mean glomerular area (MGA) and mean glomerular volume (MGV) were crucially increased in early diabetic nephropathy (P < 0.001), and the Sac group showed reduced renal pathology and improved MGA and MGV (P < 0.001).3. Kidney tissue homogenate levels of NLRP3, Caspase-1, IL1-β, TNF-α, MDA and TGF-β 1 were critically, increased in DN rats (P < 0.001), and SOD was significantly decreased. All these indicators above were improved after treatment (P < 0.0001). Conclusion: Nlrp3-inflammasome promote progression of diabetic nephropathy through inflammation, fibrosis and oxidative stress; sacubitril/valsartan ameliorated early diabetes-induced renal damage by inhibiting NLRP3 pathway activation. Keywords: diabetic nephropathy, Nlrp3-inflammasome, sacubitril/valsartan, oxidative stress, inflammation, fibrosis Diabetic nephropathy (DN) is a common complication of type 2 diabetes mellitus characterised clinically by persistent proteinuria, decreased glomerular filtration rate, elevated blood pressure and increased cardiovascular risk, 1 with pathology manifested by glomerular basement membrane thickening, thylakoid expansion, Kimmelstiel-Wilson, lesions and glomerulosclerosis, ultimately leading to tubulointerstitial fibrosis, 2,3 with poor clinical outcome and an increased risk of all-cause mortality. 4 Early intervention in disease progression is therefore an urgent clinical need. It is widely accepted that glomerular damage is the main pathological change in DN; However, in recent years, researchers have found that interstitial lesions may be an independent factor in DN progression and may occur prior to glomerular lesions, 5 with early interstitial lesions including interstitial inflammatory cell infiltration and later stages including tubular atrophy and interstitial fibrosis. Current studies suggest that NLRP3 inflammation-related molecular mechanisms are thought to participate in the development of inflammation and fibrosis and oxidative stress in the diabetic kidney. 6–8 In contrast, Sacubitril/Valsartan has been shown to have a better effect in controlling diabetic nephropathy proteinuria, delaying the decline in eGFR and improving renal pathological changes. 9–11 In this paper, we explored the biochemical and renal pathological characteristics and the expression of Nlrp3-inflammasome in rats with early diabetic nephropathy, and also explored the possible mechanisms of Sacubitril/Valsartan treatment in rats with early diabetic nephropathy, using existing studies as hypotheses. Healthy male SD rats, clean grade, about 8 weeks old, body mass 200–220g, were purchased from the Experimental Animal Centre of Bengbu Medical College (experimental animal license number: SCXK (Lu) 20190003). The rats were housed in an animal room with suitable temperature and humidity, and were subjected to a 12-h light and dark cycle, and fed and watered freely. The study was approved by the Ethics Committee of Ben -Abstract Truncated-